Cite
MLA Citation
M Jahanzeb et al.. “1398PReal-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK+ non-small cell lung cancer (NSCLC).” Annals of oncology, vol. 29, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100095516297.0x00003a